☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
mhspc
Astellas Reports Results of Xtandi (enzalutamide) in P-III ARCHES Trial for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) i...
February 12, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.